GLUE Logo

Monte Rosa Therapeutics, Inc. (GLUE) 

NASDAQ
Market Cap
$516.07M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
543 of 774
Rank in Industry
291 of 432

Largest Insider Buys in Sector

GLUE Stock Price History Chart

GLUE Stock Performance

About Monte Rosa Therapeutics, Inc.

Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, …

Insider Activity of Monte Rosa Therapeutics, Inc.

Over the last 12 months, insiders at Monte Rosa Therapeutics, Inc. have bought $0 and sold $12.3M worth of Monte Rosa Therapeutics, Inc. stock.

On average, over the past 5 years, insiders at Monte Rosa Therapeutics, Inc. have bought $276.75M and sold $12.3M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 1,050,000 shares for transaction amount of $19.95M was made by Yang Rick (10 percent owner) on 2021‑06‑28.

List of Insider Buy and Sell Transactions, Monte Rosa Therapeutics, Inc.

2024-10-29Sale10 percent owner
67,905
0.1081%
$9.16$621,801-3.79%
2024-10-28Sale10 percent owner
89,990
0.2667%
$9.66$869,2400.00%
2024-09-20Sale10 percent owner
1.13M
1.8595%
$6.53$7.4M-15.12%
2024-09-13Sale10 percent owner
9,269
0.0153%
$6.16$57,100-5.10%
2024-09-12Sale10 percent owner
16,047
0.0263%
$6.00$96,309-0.67%
2024-09-11Sale10 percent owner
541,897
0.833%
$6.00$3.25M+1.01%
2024-07-05SalePrincipal Accounting Officer
1,610
0.0027%
$3.83$6,1660.00%
2024-06-03SalePrincipal Accounting Officer
1,207
0.002%
$4.04$4,876+31.53%
2021-06-28Purchase10 percent owner
1.05M
20.5778%
$19.00$19.95M-7.95%
2021-06-28Purchase10 percent owner
1.05M
20.5778%
$19.00$19.95M-7.95%
2021-06-28Purchase10 percent owner
1.05M
20.5778%
$19.00$19.95M-7.95%
2021-06-28Purchase10 percent owner
1.05M
20.5778%
$19.00$19.95M-7.95%
2021-06-28Purchasedirector
1.05M
20.5778%
$19.00$19.95M-7.95%
2021-06-28Purchase10 percent owner
1.05M
20.5778%
$19.00$19.95M-7.95%
2021-06-28Purchase10 percent owner
1.05M
20.5778%
$19.00$19.95M-7.95%
2021-06-28Purchase10 percent owner
1.05M
20.5778%
$19.00$19.95M-7.95%
2021-06-28Purchase10 percent owner
1.05M
20.5778%
$19.00$19.95M-7.95%
2021-06-28Purchase10 percent owner
1.05M
20.5778%
$19.00$19.95M-7.95%
2021-06-28Purchase10 percent owner
1.05M
20.5778%
$19.00$19.95M-7.95%
2021-06-28Purchase
1.05M
20.5778%
$19.00$19.95M-7.95%

Insider Historical Profitability

<0.0001%
Versant Venture Capital VI, L.P.10 percent owner
1573453
2.5611%
$8.4016<0.0001%
MAKOWER JOSHUA10 percent owner
7692298
12.5207%
$8.4010<0.0001%
SANDELL SCOTT D10 percent owner
7692298
12.5207%
$8.4010<0.0001%
BASKETT FOREST10 percent owner
7692298
12.5207%
$8.4010<0.0001%
Mathers Edward T10 percent owner
7692298
12.5207%
$8.4010<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.